Bioethecist R. Alta Charo Comes To FDA After Stints On IoM Drug Safety Group, NIH Embryo Research Panel
This article was originally published in The Pink Sheet Daily
University of Wisconsin professor of law and bioethics will join FDA as a senior advisor.
You may also be interested in...
FDA is bringing in outside consultants to help improve staff interactions and build leadership in the agency's Center for Drug Evaluation and Research
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.